Mar 17, 2023 8:30am EDT Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine
Mar 07, 2023 8:30am EST Processa Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 21, 2023 8:30am EST Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
Feb 15, 2023 8:30am EST Processa Pharmaceuticals, Inc. Announces Closing of $6.25 Million Registered Direct Offering, Which Included Retail Investors and Insiders, Priced at the Market Under Nasdaq Rules
Feb 10, 2023 8:00am EST Processa Pharmaceuticals, Inc. Announces $6.25 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Jan 04, 2023 8:30am EST Processa Pharmaceuticals To Present an Update on Its Future Therapeutic Focus and Strategy at the Biotech Showcase on January 11, 2023.
Dec 14, 2022 8:30am EST Processa Pharmaceuticals Announces PCS12852 Successfully Improves the Clinical Symptoms Associated with Gastroparesis in Phase 2A Trial
Nov 08, 2022 4:00pm EST Processa Pharmaceuticals Announces Third Quarter Financial Results and Provides Corporate Update
Nov 02, 2022 8:30am EDT Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
